Previous close | 4.5000 |
Open | 4.5000 |
Bid | 3.8000 |
Ask | 6.6000 |
Strike | 7.50 |
Expiry date | 2024-09-20 |
Day's range | 4.5000 - 4.5000 |
Contract range | N/A |
Volume | |
Open interest | 16 |
Shattuck Labs (STTK) delivered earnings and revenue surprises of 21.28% and 457.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – - Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients expected to initiate enrollment in the second quarter of 2024 – - Presented preclinical data at the 2024 A
Key Insights Significantly high institutional ownership implies Shattuck Labs' stock price is sensitive to their...